Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective. [Review]
No Thumbnail Available
All Authors
Houda, I.
Dickhoff, C.
Uyl-de Groot, CA.
Damhuis, RAM.
Reguart, N.
Provencio, M.
Levy, A.
Dziadziuszko, R.
Pompili, C.
Di Maio, M.
LTHT Author
Brunelli, Alessandro
LTHT Department
Thoracic Surgery
Non Medic
Publication Date
2024
Item Type
Journal Article
Review
Review
Language
Subject
Subject Headings
Abstract
The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments. The European Medicines Agency (EMA) recently approved adjuvant osimertinib, adjuvant atezolizumab, adjuvant pembrolizumab, and neoadjuvant nivolumab combined with chemotherapy, and the approval of other agents or new indications may follow soon. Despite encouraging results, many unaddressed questions remain. Moreover, the transformed treatment paradigm in resectable NSCLC can pose major challenges to healthcare systems and magnify existing disparities in care as differences in reimbursement may vary across different European countries. This Viewpoint discusses the challenges and controversies in resectable early-stage NSCLC and how existing inequalities in access to these treatments could be addressed.
Journal
The Lancet Regional Health. Europe